Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: Results of a compassionate use program in The Netherlands

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 249-255

  Kruijtzer, C M F ^a   Verweij, J ^c   Schellens, J H M ^a,b   Beijnen, J H ^a,b   Pronk, L ^c   Bo, M ^c   Lustig, V ^a   Van Tinteren, H ^a   Mackay, M ^d   Ten Bokkel Huinink, W W ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Medical Department   (Netherlands)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Overall survival; Progression free survival; Toxicity

Indexed keywords

ANTHRACYCLINE; CORTICOSTEROID; DOCETAXEL; POLYSORBATE 80;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY REACTION; LIVER DISEASE; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NETHERLANDS; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NETHERLANDS; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0034083739     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00004     Document Type: Article

References (29)

1. 1. Piccart. Docetaxel: a new defence in the management of breast cancer. Anti-Cancer Drugs 1995; 6 (suppl 4): 7-11.
2. 2. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55.
3. 3. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part 1: preclinical experience. Anti-Cancer Drugs 1995; 6: 33-68.
4. 4. Ringel I, Band Horwitz S. Studies with RP 56976 (Taxotere): a semisynthetic analoque of Taxol. J Natl Cancer Inst 1991; 83: 288-91.
5. 5. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere®) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-32.
6. 6. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
7. 7. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
8. 8. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65.
9. 9. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
10. 10. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22.
11. 11. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210-6.
12. 2 as first-line chemotherapy for patients with advanced breast cancer: a report of the Clinical Screening Group of the EORTC. Br J Cancer 1996; 74: 650-6.
13. 13. Archer CD, Lowdell C, Sinnett J, et al. Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer 1998; 34: 816-9.
14. 14. O'Brien MER, Leonard RC, Barrett-Lee PJ, et al. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK. Ann Oncol 1999; 10: 205-10.
15. 15. Dieras V, Fumoleau P, Bourgeois H, et al. Taxoids in combination chemotherapy for metastatic breast cancer. Anti-Cancer Drugs 1996; 7 (suppl 2): 47-52.
16. 16. Ten Bokkel Huinink WW, Lustig V, Dubbelman R, et al. Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients. Eur J Cancer 1997; 33 (suppl 7): 23-5.
17. 17. Enomoto K, Abe R, Fukuda M, et al. Phase I study of combination docetaxel with cyclophosphamide in the treatment of metastatic breast cancer. Eur J Cancer 1996; 32A (suppl 2): 47.
18. 18. Kouroussis C, Andraloukis N, Kakolyris S, et al. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 862-9.
19. 19. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter Phase II trial. Ann Oncol 1999; 10: 211-5.
20. 20. Burris H. Weekly schedules of docetaxel. Sem Oncol 1998; 25 (suppl 13): 21-3.
21. 21. Tomiak C, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994; 12: 1458-67.
22. 22. Hainsworth JD, Burris HA, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-8.
23. 23. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-24.
24. 24. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel. Ann Oncol 1993; 4: 610-1.
25. 25. NCI. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute 1998.
26. 26. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Ass 1958; 53: 457-71.
27. 27. Oosterom AT. Docetaxel (Taxotere®): an effective agent in the management of second-line breast cancer. Semin Oncol 1995; 22 (suppl 13): 22-8.
28. 28. Riva A, Fumoleau P, Roche H, et al. Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere. Proc Am Soc Clin Oncol 1997; 16: 188A (abstr).
29. 29. Valero V, Jones SE, Von Hoff DD, et al A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16: 3362-8.